President, Chief Executive Officer & Member of the Management Board, Novo Nordisk A/S
No year-by-year proxy breakdown is on file — common for foreign private issuers and recently listed companies, which do not file a US proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
Weight-Loss Drugs Are Coming for Beer, Heineken Admits Privately
Oct 24, 2026https://247wallst.com/investing/2026/10/24/weight-loss-drugs-are-coming-for-beer-heineken-admits-privately/sentiment +0.30
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Oct 20, 2026https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.htmlsentiment +0.60
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Oct 16, 2026https://www.fool.com/investing/2026/10/16/forget-zepbound-3-newer-drugs-that-could-power-eli/sentiment -0.20
Walmart Stock Moves Higher: What's Happening?
Oct 14, 2026https://www.benzinga.com/trading-ideas/movers/26/10/62364387/walmart-stock-moves-higher-whats-happeningsentiment +0.20
Novo Nordisk Vs. Eli Lilly: Judged Against Big Pharma, Only One Needs A Premium
Oct 8, 2026https://seekingalpha.com/article/4952650-novo-nordisk-vs-eli-lilly-judged-against-big-pharma-only-one-needs-a-premiumsentiment +0.80
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Oct 7, 2026https://www.fool.com/investing/2026/10/06/novo-stock-is-down-more-than-70-from-its-peak-valu/sentiment -0.60
